Although glitazone therapy can reduce cardiovascular events in selected populations [129], these agents also increase the risk of clinically apparent heart failure and of fractures [129, 130], which in turn may reduce physical function and worsen sarcopenia
SeekPeptides provides comprehensive resources for understanding peptide stacking strategies, optimizing protocols, and developing evidence-based approaches to regenerative support
Study selection The criteria for including studies in this meta-analysis were as follows: (1) (i) randomized controlled trials (RCTs) comparing different AOMs with placebo, including glucagon-like peptide 1 receptor agonist (GLP-1 RA), dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RAs, GLP-1 and glucagon receptor (GCGR) dual-agonist, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and bimagrumab
Meta-analysis of the association of the haptoglobin genotype with cardiovascular outcomes and the pharmacogenomic interactions with vitamin E supplementation
Between 2006 and 2009, the FDA received 88 reports of acute pancreatitis linked to Januvia and Janumet, some of which were fatal
